Actithera
PrivateLast Round
Series A
Jul 9, 2025
Total Funding Raised
$75.5M
Momentum Score
50 /100
Company Overview
Actithera is a biotechnology company that develops radiopharmaceutical and next-generation radioligand therapies (RLTs) for cancer treatment.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Actithera Comps
Public and private peers based on sector, stage, and business model.
Actithera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 9, 2025 |
Key People
Founding team and executive leadership
Actithera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series A |
| Innovestor | Series A |
| M Ventures | Series A |
| 4Bio Capital | Series A |
| Investinor | Series A |
| Surveyor Capital | Series A |
| Bioqube Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 3, 2025
Darshan Dalal appointed as new Chief Medical Officer.
- Jul 9, 2025
$76M round completed
Actithera Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Actithera's valuation, stock price, and market status.
